NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $13.16 +0.08 (+0.61%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.94▼$13.3550-Day Range$9.40▼$13.7652-Week Range$3.06▼$14.03Volume2.80 million shsAverage Volume2.88 million shsMarket Capitalization$3.05 billionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside6.9% Downside$12.25 Price TargetShort InterestHealthy3.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 11 Articles This WeekInsider TradingSelling Shares$1.07 M Sold Last QuarterProj. Earnings Growth51.43%From $0.35 to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector676th out of 936 stocksBiological Products, Except Diagnostic Industry111th out of 154 stocks 1.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 4 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 13.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 2.5 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for ADMA Biologics this week, compared to 4 articles on an average week.Search InterestOnly 40 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows23 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 21% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,072,000.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 51.43% in the coming year, from $0.35 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -658.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -658.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 21.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesJuly 26 at 8:15 PM | marketwatch.comADMA Biologics Taps Brad Tade as CFOJuly 24 at 8:54 PM | msn.comAdma Biologics (ADMA) Stock Moves -1.31%: What You Should KnowJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.July 22, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Reaches New 1-Year High at $13.84July 21, 2024 | ca.finance.yahoo.comCORT Aug 2024 31.000 callJuly 21, 2024 | americanbankingnews.comNKGen Biotech (NYSE:NKGN) versus ADMA Biologics (NASDAQ:ADMA) Head to Head ComparisonJuly 19, 2024 | finance.yahoo.comZacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept TherapeuticsJuly 17, 2024 | 247wallst.comAdd These 5 Hot Biotech Stocks In JulyJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.July 13, 2024 | investorplace.com3 Millionaire-Making Stock Picks With Astounding Growth PotentialJuly 11, 2024 | investorplace.comBull Run Alert: 3 Stocks Set to Soar in the Coming MonthsMay 12, 2024 | seekingalpha.comGiving ADMA Biologics A Well-Deserved 'Booyah'May 11, 2024 | cnn.comADMA Biologics, Inc.May 11, 2024 | finance.yahoo.comADMA Biologics First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comStrong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA BiologicsMay 10, 2024 | marketwatch.comADMA Biologics Shares Rise 23% After 1Q Earnings Beat EstimatesMay 10, 2024 | msn.comADMA Biologics hits 52-week high on Q1 beat, guidance raiseMay 10, 2024 | finance.yahoo.comADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024See More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside-6.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio37.60 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins-1.29% Pretax Margin-1.08% Return on Equity17.24% Return on Assets7.38% Debt Debt-to-Equity Ratio0.91 Current Ratio5.21 Quick Ratio1.86 Sales & Book Value Annual Sales$258.21 million Price / Sales11.81 Cash Flow$0.05 per share Price / Cash Flow267.23 Book Value$0.60 per share Price / Book21.93Miscellaneous Outstanding Shares231,810,000Free Float223,232,000Market Cap$3.05 billion OptionableOptionable Beta0.55 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO, Interim CFO & Director Comp: $1.59MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $90kMs. Kaitlin Kestenberg (Age 37)COO & Senior VP of Compliance Mr. Drew PantelloVice President of Marketing & Corporate DevelopmentMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMr. Brad TadeVice President of Financial OperationsMore ExecutivesKey CompetitorsSolid BiosciencesNASDAQ:SLDBLogicBio TherapeuticsNASDAQ:LOGCChampions OncologyNASDAQ:CSBRCatalentNYSE:CTLTQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 49,631 shares on 7/26/2024Ownership: 0.331%Allspring Global Investments Holdings LLCSold 41,808 shares on 7/26/2024Ownership: 0.091%Calamos Advisors LLCBought 46,405 shares on 7/25/2024Ownership: 0.260%China Universal Asset Management Co. Ltd.Sold 16,636 shares on 7/20/2024Ownership: 0.012%Nisa Investment Advisors LLCSold 199,828 shares on 7/20/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $4.52 on January 1st, 2024. Since then, ADMA stock has increased by 191.2% and is now trading at $13.16. View the best growth stocks for 2024 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. The firm's revenue was up 43.9% compared to the same quarter last year. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are ADMA Biologics' major shareholders? Top institutional shareholders of ADMA Biologics include Assenagon Asset Management S.A. (1.46%), Bank of New York Mellon Corp (0.33%), Calamos Advisors LLC (0.26%) and SG Americas Securities LLC (0.16%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Young Kwon, Bryant Fong and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO) and Novan (NOVN). This page (NASDAQ:ADMA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
